| 27 | 1 | 4 |
| 下载次数 | 被引频次 | 阅读次数 |
目的 :探讨普伐他汀治疗老年人高脂血症的临床效应和安全性。方法 :将 43例老年高脂血症患者随机分为两组 :普拉固组和多烯康组 ,治疗 8周后观察血脂变化和安全性 ,并加以比较。结果 :普拉固组能显著降低老年人的血清 TC、L DL -C、apo- B,升高 HDL- C、apo A1 、apo A1 / apo B,明显优于多烯康组。结论 :普伐他汀具有显著的降脂作用和调脂功能 ;安全性方面 ,未发现有临床意义的毒副作用
Abstract：Objective: To study clinical efficary and safety of pravastatin on olderly hypercholesterolemia. Methods: Forty-three olderly hypercholesterolmia patients were divided into pravastatin group (n=28) and doxicang group (n=25), The lipid and safety was study after eight weeks. Results: There were lower levels of oderly TC、 LDC-C、 apoB and higher HDL-C、 apoA 1/apoB, all in pravastatin group than doxicang group. Conclusion: Pravastatin is good effective and safe in the treating olderly hypercholesterolemia.
1 Scandinavian Simvastatin Survival Study Group. Ran-domised trial of cholesterol L owering in 44 44 patientswith coronary heart disease:the Scandinavian Sim vas-tatin Survival Study (4 s) . L ancet,1994,344 :1383-1389
2 Holme I. Cholesterol reduction and its im pact on coro-nary artery disease and total mortality. Am J Cardiol,1995 ,76 :10 - 17
3 Shepherd J,Cobbe SM,Ford I,et al. Prevention ofcoronary heart disease with pravastatin in m en with hy-percholesterolemia. N Engl J Med,1995 ,333:130 1-130 7
4 Byington RP,Jukema JW,Salonen JT,etal. Reductionin cardiovascular events during pravastatin therapy:pooled analysis of clinical events of the pravastatinatherosclerosis intervention program . Circulation,1995 ,92 :2 419- 2 42 5 .
5 Sacks FM,Pfeffer MA,Moye L A ,et al. The effect ofpravastatin on coronary events after myocardial infarc-tion in patients with average cholesterol levels. N Engl JMed,1996 ,335 :10 0 1- 10 0 9
6 伍卫 ,张旭明 .基础血脂水平对血汀类药物降脂作用的影响 .中华内科杂志 ,1994,4:2 6 3
7 汪芳 ,高明 ,崔建平 .老年高血压患者的脂质状态分析 .中国心血管杂志 ,1997,12 :2 15 - 2 17
8 Gordon T,Kannel WB. Multiple risk functions for pre-dicting ceronary heart disease:the concept accuracy andapprication. Am Heart J,1982 ,6 :10 31- 10 37
9 Weir MR,Berger ML ,Weeks ML ,et al. Com parisonof the effects on quality of life and of the efficary andtolerability of lovastatin versus pravastatin. Am JCardi-ol,1996 ,3:475 - 479
10 Glasser SP,Di Bianco R,Effron BA,et al. The effi-cary and safety of pravastatin in patients aged 6 0 to 85years with low- Density lipoprotein cholesterol>16 0 m g/dl.The Am erican Journal of Cardiology,1996 .1:83- 85 .
11 Sacks FM,Moye L A,Davis BR,et al.Relationshipbetween plasma L DL Concentrations During Treat-ment With Pravastatin and recurrent coronary eventsin the cholesterol and recurrent events Trial.Circula-tion,1998,97:144 6 - 145 2
12 Stein EA,L ame M,L askazewski P.Com parison ofstatins in hypertriglyceridemia.Am Jcardiol,1998,81(4 A) :6 6 B- 6 9B.
基本信息:
DOI：
中图分类号:R589.2
引用信息:
[1]张刚成,钟耀生.小剂量普伐他汀治疗中国老年人高脂血症的效应和安全性[J].武汉市职工医学院学报,2000(03):11-12+40.
基金信息: